EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of Reactive Oxygen Species in Lung Cancer Development: Nanomedicine as a Therapeutic Strategy

Manuel Olazábal-Morán, Elena Pérez, Adrián Esteban-Arranz iD, Antonio Garrido iD

Biomolecules · 2025

DOI: 10.3390/biom15091316 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Manuel Olazábal-Morán und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nanocaging Research Group, Department of Biosciences, School of Biomedical and Health Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, …. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Lung Neoplasms, Nanomedicine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer remains a leading cause of mortality worldwide, driven by increased tobacco use, industrialization, and air pollution. Despite advancements in diagnostics and treatments, effective therapies are still lacking. Reactive oxygen species (ROS) play a dual role in cancer development, regulating key signaling pathways and activating cell death pathways, making them a promising target for new drugs. Research shows that wild-type NRF2/KEAP1 lung tumors, which account for about 60% of lung malignancies, are sensitive to ROS induction, and mutated EGFR1 lung tumors exhibit high ROS levels. Proteolysis-targeting chimeras (PROTACs) have emerged as a promising alternative to small molecule inhibitors (SMIs) for cancer treatment, addressing limitations like undruggability and drug resistance. However, these face challenges such as limited cell penetration and potential toxic side effects. Nanotechnology has introduced “nano-PROTACs,” enhancing tissue accumulation, membrane permeability, and controlled release. In this review, the keystones of ROS in lung cancer will be summarized. Also, a potential therapy for tumors with wild-type NRF2 involving the delivery of ROS inductor nano-PROTAC will be designed. This potential therapy could suppose a potential therapeutic strategy for lung cancer patients with these genetic characteristics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reactive Oxygen SpeciesLung NeoplasmsNanomedicineHumansAnimalsNF-E2-Related Factor 2Antineoplastic AgentsSignal Transduction

Stichwörter der Autor:innen

NRF2ROSlung cancernano PROTACsnanomedicinetargeted therapy

Substanzen

Reactive Oxygen SpeciesNF-E2-Related Factor 2Antineoplastic Agents

Autor:innen und Institutionen

  • Nanocaging Research Group, Department of Biosciences, School of Biomedical and Health Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, 28670 Madrid, Spain.
  • Nanocaging Research Group, Department of Pharmacy and Nutrition, School of Biomedical and Health Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, 28670 Madrid, Spain.

ORCID-Profile: Adrián Esteban-Arranz, Antonio Garrido

Zitieren

APA

Olazábal-Morán, M., Pérez, E., Esteban-Arranz, A., & Garrido, A. (2025). The Role of Reactive Oxygen Species in Lung Cancer Development: Nanomedicine as a Therapeutic Strategy. Biomolecules. https://doi.org/10.3390/biom15091316

Vancouver

Olazábal-Morán M, Pérez E, Esteban-Arranz A, Garrido A. The Role of Reactive Oxygen Species in Lung Cancer Development: Nanomedicine as a Therapeutic Strategy. Biomolecules. 2025. doi:10.3390/biom15091316

BibTeX
@article{OlazbalMorn2025,
  author = {Olazábal-Morán, Manuel and Pérez, Elena and Esteban-Arranz, Adrián and Garrido, Antonio},
  title = {The Role of Reactive Oxygen Species in Lung Cancer Development: Nanomedicine as a Therapeutic Strategy},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15091316}
}
Kostenlos starten →